Finance

Beta
Lists
PRME:NASDAQ
Prime Medicine, Inc
$3.37
+4.33%
(+0.14) 1D
$3.45
+2.37% (+0.080)
After hours
Closed: Jun 22, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PRME...
Open
$3.33
High
$3.57
Low
$3.30
Mkt. cap
608.68M
Avg. vol.
2.91M
Volume
3.50M
52-wk high
$6.94
52-wk low
$2.02
EPS
-$1.26
Beta
2.31
Shares outstanding
180.62M
No. of employees
146
Open
$3.33
High
$3.57
Low
$3.30
Mkt. cap
608.68M
Avg. vol.
2.91M
Volume
3.50M
52-wk high
$6.94
52-wk low
$2.02
EPS
-$1.26
Beta
2.31
Shares outstanding
180.62M
No. of employees
146
News stories
From sources across the web
Profile
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts. Wikipedia
About Prime Medicine, Inc
CEO-
Employees146
Founded2019
Headquarters-
SectorBiotechnology
Websiteprimemedicine.com
Analyst Ratings
Based on 8 analysts giving stock ratings to PRME in the past 3 months
Strong Buy
Buy
6
Hold
2
Sell
0
12 month forecast
Based on 8 Wall Street analysts offering 12 month price targets for PRME in the last 3 months.
Highest
Current $3.37
$11.00 (+226.41%)
Average
$7.80 (+131.45%)
Lowest
$5.00 (+48.37%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Cory Jubinville, PhD
LifeSci Capital
Buy
Maintained
$6.00
+78%
06/18/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
-
-
06/18/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$11.00
+226.4%
05/12/2026
Boris Peaker
JonesTrading
Buy
Reiterated
$5.00
+48.4%
05/08/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$9.00
+167.1%
05/08/2026
Unknown Analyst
Wedbush
Buy
Maintained
$8.00
+137.4%
05/08/2026
Arthur He CFA
H.C. Wainwright
Hold
Reiterated
-
-
05/08/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
05/07/2026
Soumit Roy
JonesTrading
Buy
Maintained
$5.00
+48.4%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.12M
1.22M
838.00K
856.00K
Cost of goods sold
3.22M
43.99M
34.71M
34.10M
Cost of revenue
3.22M
43.99M
34.71M
34.10M
Research and development expenses
38.16M
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.12M
11.21M
14.74M
17.40M
Operating expense
51.27M
11.21M
14.74M
17.40M
Total operating expenses
54.49M
55.20M
49.45M
51.51M
Operating income
-53.38M
-53.97M
-48.61M
-50.65M
Other non operating income
18.00K
44.00K
49.00K
51.00K
EBT including unusual items
-52.59M
-50.58M
-46.08M
-49.12M
EBT excluding unusual items
-52.62M
-52.79M
-47.48M
-49.58M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-52.59M
-50.58M
-46.08M
-49.12M
Net profit margin
-4,716.68%
-4,129.14%
-5,498.69%
-5,738.55%
Earnings per share
-0.41
-0.32
-0.24
-0.28
Interest and investment income
743.00K
1.14M
1.08M
1.02M
Interest expense
-
-
-
-
Net interest expenses
743.00K
1.14M
1.08M
1.02M
Depreciation and amortization charges
-
-
-
-
EBITDA
-51.51M
-52.09M
-46.73M
-48.80M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer